XTLB vs YDES

XTL Biopharmaceuticals Ltd. vs YD Bio Limited — Valuation Comparison 2026

XTLB

Biotechnology
XTL Biopharmaceuticals Ltd.
Quality
1.7
out of 10
Value Trap
Price
$2.46
Last close
Models
6/13
Active
VS

YDES

Biotechnology
YD Bio Limited
Quality
2.3
out of 10
Value Trap
Price
$3.51
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType XTLB Fair ValueXTLB Upside YDES Fair ValueYDES Upside
Bayesian DCF Intrinsic $0.65 -73.5% $0.93 -73.5%
Earnings Power Value Intrinsic $0.12 -97.5%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $0.72 -71.6% $0.10 -98.0%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for XTLB vs YDES — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XTLB vs YDES — Which Stock Is More Undervalued?

YDES scores higher with a 2.3/10 quality rating vs XTLB's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing XTL Biopharmaceuticals Ltd. (XTLB) and YD Bio Limited (YDES) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XTLB currently trades at $2.46 with a QOC of 1.7/10, while YDES trades at $3.51 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).